Kiwamu Imagawa ＪＣＲ Pharmaceuticals Co., Ltd. / AlliedCel Corporation

Joined JCR Pharma Co., Ltd. (then Japan Chemical Research Co., Ltd.) in 1998. In 2003, research and development of "human mesenchymal stem cell products" began. Since the start of development, he has been engaged in this work, mainly CMC. He has experienced a series of tasks, starting with technology transfer from a US licensor, developing manufacturing methods, conducting clinical trials, and applying for and obtaining approval. In September 2015, Japan's first human (allogeneic) regenerative medicine product, "TEMCELL® HS Injection," was approved. He is currently engaged in research and development of new regenerative medicine products at JCR Pharma Co., Ltd. and AlliedCel Co., Ltd., which was established in 2022 with Sysmex Corporation. 

Graduated from the Kobe University Graduate School of Medicine (PhD course). Doctor of Medicine.